Page 2 - Devin Mclaughlin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

CHICAGO — A chemotherapy de-escalation strategy involving dual HER2 blockade resulted in high rates of 3-year invasive DFS among patients with HER2-positive early breast cancer, according to study results presented at ASCO Annual Meeting.The findings appeared consistent with those of studies that explored a combination of neoadjuvant chemotherapy and dual HER2-targeted treatments, with no

CHICAGO — One-third of women oncologists surveyed reported experiencing infertility, according to study results presented at ASCO Annual Meeting.In addition, survey respondents reported feeling fertility preservation could have been helpful if it were available and affordable.

CHICAGO — Assessment of RUBY trial outcomes by blinded independent central review confirmed the benefits of adding dostarlimab to chemotherapy for women with primary advanced or recurrent endometrial cancer.The findings, presented at ASCO Annual Meeting, showed clinically meaningful PFS improvement with the dostarlimab (Jemperli, GSK) regimen vs. chemotherapy alone among women with mismatch

CHICAGO — Nearly one-fourth of academic oncologists surveyed reported feelings of burnout, with the highest rates among women and lesbian/gay/bisexual faculty, according to study results presented at ASCO Annual Meeting.The findings indicate an urgent need for tailored interventions at all levels to address factors driving burnout and its impact on attrition and career trajectory for

CHICAGO — One-year of adjuvant trastuzumab remains the standard-of-care treatment duration for most patients with HER2-positive early breast cancer, according to study results presented at ASCO Annual Meeting.However, certain patients with low/intermediate HER2-positive early breast cancer may benefit from a shorter, 9-week course of trastuzumab (Herceptin, Genentech), researchers noted.